Topics:
Melanoma/Skin Cancer • Medical Oncology
How often are you recommending adjuvant pembrolizumab for resected stage IIB/C melanoma patients?
Based on the KEYNOTE-716 study and Dec 2021 FDA approval
Answer from: Medical Oncologist at Academic Institution
Will refer to the results from the KEYNOTE-716 trial:The data cutoff for the analysis (in January 2022), median follow-up was 27.4 months (interquartile range = 23.1–31.7 months). Pembrolizumab significantly improved distant metastasis–free survival vs placebo (hazard ratio [HR] = 0.64, ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The patient should be enrolled on KEYNOTE-716 (Phase 3 study of pembro vs placebo for high risk stage II melanoma including T3b, T4a, T4b) - https://clinicaltrials.gov/ct2/show/NCT03553836?term=KEYNOTE+716&rank=1.
Comments
Medical Oncologist at St Jude Heritage Medical Group
So we can surmise from your answer that since KEYN...
So we can surmise from your answer that since KEYN...